by TractManager | Nov 26, 2019 | Emerging Technology Report
Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS...
by TractManager | Nov 26, 2019 | Emerging Technology Report
Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS...
by TractManager | Nov 25, 2019 | Emerging Technology Report
Caplacizumab is a subcutaneously injected biologic agent intended for use as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to...
by TractManager | Nov 25, 2019 | Health Technology Assessment
Health Problem: Colorectal cancer (CRC) is the second leading cause of cancer death in men and the third in women. Although screening for CRC has been found to reduce CRC mortality, many patients do not undergo the recommended screening. Technology Description: Colon...
by TractManager | Nov 25, 2019 | Emerging Technology Report
Caplacizumab is a subcutaneously injected biologic agent intended for use as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to...
Recent Comments